Medipol University Hospital is a major private academic medical center in Istanbul, combining specialist clinical care with medical education and research through its affiliation with Istanbul Medipol University. Its services span areas including oncology, cardiovascular care, neurology, surgery, pediatrics and intensive care. The hospital also serves a substantial international patient population and forms part of the wider Medipol Health Group.
Can you give us a sense of the scale of Medipol University Hospital and its place within the wider Medipol Health Group?
Medipol Mega University Hospital is our largest complex, with 810 beds, and each patient room is designed for a single patient. It brings together the major medical and surgical specialties and is also a major teaching site for Istanbul Medipol University. We have around 400 physicians, roughly half of whom are academic faculty, approximately 250 residents and around 1,500 nurses. On a typical day, close to 1,000 students may also come through the hospital for clinical education.
Across the wider Medipol Health Group, we operate 12 hospitals with nearly 3,000 beds. The scale is important because it allows us to combine clinical care, education and research in one system rather than treating them as separate activities.
What are the advantages and difficulties of operating so many specialist services within one complex?
The advantage is that we have a strong quality-management structure. JCI standards place patient safety at the center of hospital operations, while university hospitals also work within Türkiye’s higher-education regulations and medical-education quality systems. If you have a good, high-quality system, the job is not so hard. These frameworks help us coordinate a very large and complex institution.
The challenge is simply the volume. We see almost 4,000 outpatients and perform around 100–120 operations every day. Orchestrating that capacity is not easy. If we had more physical space, more elevators and more classrooms for students, it would make operations easier. Those physical constraints become increasingly important as patient activity and teaching continue to grow.
How does Medipol’s relationship with the university shape patient care, medical education and research?
The hospital and university work as one ecosystem. Of our roughly 400 physicians, about half are university faculty, and we have around 250 residents training and working in the hospital. Students from medicine, nursing and other health disciplines learn directly in the clinical environment, while academic and hospital teams collaborate on patient care.
That same model supports interdisciplinary research and publication. Projects are developed jointly by university faculty, hospital clinicians and administrators. [This research model is increasingly international: in 2026, Medipol’s SABITA institute convened researchers from several countries for R3FINE 2026, focused on new approaches to biomedical research.] For us, education, research and clinical practice should reinforce one another rather than operate in isolation.
What treatments are driving international patients to Medipol, and how do you support them before and after treatment?
Oncology is one of our strongest areas because it brings together medical oncology, radiation oncology and surgical oncology, including colorectal, urological, head-and-neck and neurosurgical cancer care. Cardiology and cardiovascular surgery are also important, as are pediatrics and its subspecialties, neurosurgery, neonatal care and intensive care. Medipol currently treats around 34,000 international patients each year, and patients from 167 countries have been treated in recent years.
Libya is our largest source market, followed by Turkmenistan, Uzbekistan, Syria, Iraq, Azerbaijan, Russia, Iran, Kazakhstan, Germany and Ukraine. The most frequently used specialties are obstetrics and gynecology, ophthalmology, ENT, pediatrics, orthopedics and traumatology, neurology, dermatology, general surgery, check-ups, and physical medicine and rehabilitation. Our International Patient Services network has offices in 16 countries and 21 cities, provides services in 30 languages, works with 3,054 international partners and has 198 staff at Mega and 264 across Medipol. We provide free second opinions, online consultations, interpreting and airport-hotel-hospital transfers; online consultation also provides a channel for follow-up after patients return home. We operate 79 guesthouse units, from studios to two-bedroom apartments, and a 35-vehicle transfer fleet. [Around 350 overseas healthcare professionals also come to Medipol each year for training.]
Where are digital systems and AI having the clearest effect on everyday hospital operations?
We are already using AI across several areas rather than treating it as a single clinical project. It is used in financial and business systems, research programs and performance management. Within our quality framework, we track KPIs with AI-supported systems, which can help us monitor performance across a very large organization.
Research is another important area. We encourage physicians to produce high-quality Q1 and Q2 publications, and AI-supported tools are increasingly part of project development and research workflows. The opportunity is to use these systems to make both the administrative and academic sides of the hospital more efficient.
What are the most difficult workforce challenges facing Medipol, particularly in nursing and highly specialized care?
Nursing is our biggest workforce challenge. Türkiye has roughly 1,500 hospitals: around 1,000 public hospitals and 500 private hospitals. The overall supply of nurses is limited, and many nurses prefer to work in the public sector, which creates particular recruitment and retention pressure for private hospitals.
This is especially significant at our scale. A hospital with around 1,500 nurses, high daily patient volumes, intensive care units and highly specialized services needs a reliable workforce at every level. For us, nursing availability remains one of the most important constraints.
What is the greatest constraint on Medipol’s next phase of development, and what are you doing to strengthen the university’s global standing?
Our priority is to raise the university’s international academic standing. Research is fundamental to that. We need more high-level publications, particularly Q1 and Q2 papers, but this takes time: a Q1 publication can take almost two years. Building research quality is therefore not something that can be achieved overnight. “Our ambition is to keep moving upward and ultimately reach the top 500.”
There has already been progress. Istanbul Medipol University is in the 801–1000 band in the Times Higher Education World University Rankings 2026, up from 1501+ the previous year. Medipol reported that its 2026 Medical and Health subject ranking rose from 1001+ to 601–800, while QS places it in the 701–850 band for medicine in 2026. The next step is to increase research capacity, publication quality and international collaboration while continuing to integrate the university more closely with the hospital system.
